✦ LIBER ✦

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study

✍ Scribed by Jones, Stephen E; Collea, Rufus; Paul, Devchand; Sedlacek, Scot; Favret, Anne M; Gore, Ira; Lindquist, Deborah L; Holmes, Frankie Ann; Allison, Mary Ann K; Brooks, Barry D; Portillo, Raul M; Vukelja, Svetislava J; Steinberg, Michael S; Stokoe, Christopher; Crockett, Maria W; Wang, Yunfei; Asmar, Lina; Robert, Nicholas J; O'Shaughnessy, Joyce

Book ID: 121365753
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 210 KB
Volume: 14
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(13)70384-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A pilot study of adjuvant nanoparticle a

A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer

✍ Denise Yardley; Howard Burris; Nancy Peacock; Eric Raefsky; Marianne Melnik; Rog 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 171 KB

A phase I/II prospective, single arm tri

A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer

✍ G. Somlo; C. L. Martel; S. K. Lau; P. Frankel; C. Ruel; L. Gu; A. Hurria; C. Chu 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 229 KB

Subcutaneous versus intravenous administ

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial

✍ Gustavo Ismael; Roberto Hegg; Susanne Muehlbauer; Dominik Heinzmann; Bert Lum; S 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 245 KB

1BA Subcutaneous Administration of Trast

1BA Subcutaneous Administration of Trastuzumab in Patients with HER2-positive Early Breast Cancer: Results From the Phase III Randomised, Open-label, Multi-centre Neoadjuvant-adjuvant HannaH Study

✍ C. Jackisch; D. Stroyakovskiy; S. Muehlbauer; D. Heinzmann; M.V. Kopp; J.S. Ahn; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 58 KB

2129 POSTER An open-label study of capec

2129 POSTER An open-label study of capecitabine (C) and docetaxel (D) as neoadjuvant treatment for patients with recently diagnosed HER2-neu negative (HER2–) breast cancer (BC) plus trastuzumab (T) for HER2-neu positive (HER2+) BC

✍ D. Tripathy; C. Moisa; S. Glück 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 61 KB

Phase II Study of Neoadjuvant Docetaxel,

Phase II Study of Neoadjuvant Docetaxel, Vinorelbine, and Trastuzumab Followed by Surgery and Adjuvant Doxorubicin Plus Cyclophosphamide in Women With Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancer

✍ Glück, S. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 70 KB